What is Sano Genetics?
Founded by a team of Ph.D. researchers from the University of Cambridge, Sano Genetics operates a sophisticated platform that empowers individuals to contribute their genetic and medical data to high-impact research studies and clinical trials. By prioritizing user privacy and data transparency, the company addresses critical bottlenecks in the drug discovery and personalized medicine pipeline. Its market position is defined by its ability to streamline patient recruitment and data accessibility, providing pharmaceutical and biotech partners with the high-quality insights necessary to accelerate therapeutic development. As the industry shifts toward precision medicine, Sano Genetics serves as a vital infrastructure layer for the next generation of medical breakthroughs.
How much funding has Sano Genetics raised?
Sano Genetics has raised a total of $25.8M across 3 funding rounds:
Angel/Seed
$3.4M
Series A
$11M
Other Financing Round
$11.4M
Angel/Seed (2021): $3.4M with participation from January Ventures, Seedcamp Ltd, Episode 1 Ventures LLP, and Cambridge Enterprise
Series A (2022): $11M led by MMC Ventures
Other Financing Round (2024): $11.4M supported by Plural
Key Investors in Sano Genetics
Plural
Plural is a strategy consultancy helping businesses to deliver transformational growth, advising major corporates and private equity investors across the media, information, and technology sectors.
Episode 1 Ventures LLP
Episode 1 Ventures is a London-based venture capital firm that specializes in early-stage software-driven businesses with high growth potential, often acting as the first institutional investor.
MMC Ventures
MMC Ventures is a dedicated investor that helps scale technology companies transforming today's markets, providing deep operational support from the Seed and Series A stages.
What's next for Sano Genetics?
With the successful closure of this major enterprise-level funding, Sano Genetics is well-positioned to scale its operations and expand its reach within the global clinical trial market. The strategic deployment of this capital will likely focus on enhancing the platform's data processing capabilities, strengthening partnerships with global pharmaceutical entities, and broadening the scope of its research initiatives. As the company matures, its focus will remain on maintaining its competitive edge in data security while scaling its user base to provide more comprehensive, diverse datasets for medical innovation. The firm's ability to navigate the complex regulatory landscape of genetic data will be a defining factor in its long-term success and market leadership.
See full Sano Genetics company page
